This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Looking into the phase 1 data on Intellia Therapeutics' NTLA-2002 in patients with hereditary angioedema.
Ticker(s): NTLAWho's the expert?
Institution: ProHealthcare
- Allergist treating 13 patients with HAE
- Medical education at Emory University, St. Jude’s Children’s Hospital, the University of Tennessee, and the Albert Einstein College of Medicine New York.
- Provides testing for environmental and food allergies, pulmonary function testing, laboratory evaluation of immunity, and general allergy and immune consultations.
Interview GoalThis call will focus on the recent results from the phase 1 study of Intellia Therapeutics' CRISPR therapy NTLA-2002 in patients with hereditary angioedema.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
